["Active" endoprosthesis with in situ release of an antimitotic or cytostatic drug: a revolution that cannot do without thought].
Service de cardiologie générale, clinique Pasteur, 31076 Toulouse 1, France. marco@interv-cardio-toul.fr
J
J
Marco
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000628:therapy*; D016503:Drug Delivery Systems; D000068338:Everolimus; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015607:Stents
D000970:Antineoplastic Agents; D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus